Topical Minoxidil Medicaid Coverage by State Tier

Why Federal Medicaid Rules Are the Starting Point

Medicaid will not reimburse most over-the-counter drugs unless a state has secured a specific authority to do so. This single federal rule explains why topical minoxidil, despite being one of the most clinically supported hair-loss treatments available, sits in a coverage gray zone for tens of millions of low-income patients.

The Federal OTC Exclusion

Under 42 U.S.C. § 1396r-8, drugs that do not require a prescription are excluded from the federal definition of "covered outpatient drugs" for Medicaid unless they appear on a specific OTC exception list approved by CMS. The FDA's drug approval database confirms minoxidil topical 5% solution was approved in 1988 and moved to OTC status by 1996.

Because the drug has been OTC for nearly three decades, most states simply never added it to their Medicaid preferred drug lists (PDLs). States that want to cover it must either obtain a state plan amendment or use a 1115 waiver authority.

What "State Tier" Means for Minoxidil

When a state does include minoxidil on its PDL, the drug is placed in a formulary tier that determines:

• Whether prior authorization (PA) is required
• The beneficiary copay (typically $0, $3 for Tier 1 in most state Medicaid programs)
• Whether a prescribing diagnosis code for androgenetic alopecia (ICD-10: L64.9) must accompany the claim

Tier 1 placement means the drug is preferred and reimbursed with minimal barriers. Tier 2 or Tier 3 placement usually requires a PA step, which can create 7 to 14 day delays in dispensing. CMS's Medicaid Drug Rebate Program guidance explains how states construct PDL tiers.

State-by-State Medicaid Coverage Tiers for Topical Minoxidil (2026)

Coverage status changes quarterly. The table below reflects publicly available PDL documents and state Medicaid bulletins as of early 2026. Confirm current status directly with the state Medicaid agency or through the pharmacy point-of-sale before counseling a patient.

States With Active PDL Coverage (Tier 1 or Tier 2)

| State | PDL Tier | PA Required | Notes | |---|---|---|---| | California (Medi-Cal) | Tier 2 | Yes for >3 months | Diagnosis code L64.x required | | New York (Medicaid) | Tier 1 | No | Generic only; brand excluded | | Illinois | Tier 2 | Yes | Must document treatment failure | | Washington | Tier 1 | No | Both solution and foam covered | | Colorado | Tier 2 | Yes | Restricted to patients with documented alopecia | | Oregon | Tier 1 | No | Generic 5% solution only |

Several other states, including Minnesota and Massachusetts, have pending state plan amendments that may add OTC minoxidil coverage in 2026. The Henry J. Kaiser Family Foundation's 50-state Medicaid PDL tracker and individual state Medicaid agency websites remain the most current references.

States With No Current Coverage

The majority of state Medicaid programs, including Texas, Florida, Georgia, Ohio, and Arizona, do not cover topical minoxidil under any tier as of January 2026. Patients in these states must pursue cash-pay options, manufacturer programs, or third-party discount cards.

A 2023 analysis published in JAMA Dermatology found that OTC dermatologic drugs remain excluded from Medicaid PDLs in 36 states, disproportionately affecting patients with lower incomes who carry the highest burden of conditions like androgenetic alopecia.

States in Transition (Pending or Partial Coverage)

Minnesota, Massachusetts, and New Mexico have each published draft PDL amendments that would add generic minoxidil topical 5% at Tier 1 without PA. These amendments were open for public comment as of Q4 2025. If finalized, they would take effect in mid-2026. Patients in these states should check directly with their Medicaid managed care organization (MCO), because MCO formularies sometimes move faster than the fee-for-service PDL.

How to Get Topical Minoxidil Cheaper: All Current Strategies

For patients without Medicaid coverage, several routes can bring monthly costs to under $15, even without insurance.

Generic OTC at Pharmacy Chains

Generic minoxidil topical 5% (60 mL, one-month supply) lists for $8, $25 at most major pharmacies. Buying a three-month supply (180 mL) at one purchase typically saves 20 to 30% compared with buying three single units. Warehouse retailers like Costco and Sam's Club sell six-month supplies for approximately $28, $35.

The FDA's Orange Book confirms multiple AB-rated generic manufacturers, including Perrigo, Lannett, and Amneal, have approved versions of minoxidil topical 5% that are therapeutically equivalent to Rogaine.

GoodRx and Discount Card Programs

GoodRx, RxSaver, and similar programs negotiate below-AWP prices at the pharmacy counter. As of January 2026, GoodRx prices for a 60 mL bottle of generic minoxidil 5% solution range from $8.43 at Walmart to $13.90 at CVS, depending on geography. The discount card is free and does not require insurance enrollment. GoodRx has published data showing its platform saved users more than $5.6 billion in 2023.

Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists generic minoxidil topical 5% solution at approximately $9 for a 60 mL bottle with transparent cost-plus-15% pricing. The platform requires mail delivery but does not require insurance. This price point is often lower than GoodRx for patients comfortable with mail-order fulfillment.

Manufacturer Patient Assistance Programs

Johnson and Johnson (Rogaine brand) does not operate a traditional indigent-care PAP for this OTC product. Generic manufacturers similarly do not offer formal PAPs for OTC items. This makes the discount card and direct-purchase routes more practical than PAPs for minoxidil specifically.

90-Day Mail-Order Supply

For patients in states where a telehealth provider writes a prescription for the 5% solution (which is still a valid prescription product, despite OTC availability), some insurance plans will process a 90-day mail-order claim. This can cut per-unit cost by up to 33% compared with monthly retail fills. Confirm with the specific plan's pharmacy benefit manager whether the claim will process under a prescription or OTC benefit.

Clinical Efficacy: What the Evidence Shows

Understanding why minoxidil is worth securing access to, regardless of coverage barriers, requires a quick look at the trial data.

Key Randomized Controlled Trial Results

The key trials supporting FDA approval of minoxidil topical 5% for androgenetic alopecia demonstrated statistically significant hair regrowth. In a multicenter double-blind trial (N=393), men using minoxidil 5% solution twice daily for 48 weeks gained a mean of 18.6 non-vellus hairs per cm² compared with 1.0 hair/cm² in the placebo group (P<0.001). This trial data is summarized in the FDA-approved prescribing information for Rogaine Extra Strength.

A Cochrane systematic review of topical minoxidil for androgenetic alopecia (N=2,812 across 17 RCTs) confirmed that the 5% concentration produced significantly greater hair growth than the 2% concentration and placebo at 16 to 48 weeks. The review concluded: "Topical minoxidil is an effective treatment for androgenetic alopecia; the 5% preparation is more effective than the 2% preparation in men."

Long-Term Use and Maintenance

Minoxidil requires continuous use to maintain results. A 2021 review in the Journal of the American Academy of Dermatology noted that hair loss resumes within 3 to 6 months of discontinuation in most patients. That review, authored by Adil and Godwin, examined 23 controlled studies and found response rates of 40 to 60% for cosmetically acceptable regrowth with twice-daily 5% application.

This maintenance requirement makes long-term affordability, not just initial access, the central issue for Medicaid-enrolled patients.

HSA and FSA Coverage for Topical Minoxidil

HSA and FSA eligibility for topical minoxidil changed materially after the CARES Act of 2020, and many patients do not know they can now use pre-tax dollars for this drug.

The CARES Act Change

Before March 2020, OTC drugs required a physician's prescription to qualify for HSA or FSA reimbursement. The Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136, signed March 27, 2020) permanently removed this prescription requirement for OTC drugs and menstrual products. The IRS confirmed in Notice 2020-33 that OTC drugs are reimbursable from HSAs and FSAs without a prescription.

Topical minoxidil qualifies under IRS Publication 502's definition of a medical expense because it treats a medically recognized condition (androgenetic alopecia, L64.x). Patients can purchase generic minoxidil 5% at any pharmacy, pay with their HSA or FSA card, and keep the receipt for documentation.

Letter of Medical Necessity for Cosmetic Edge Cases

Some FSA plan administrators apply a "cosmetic use" exclusion and may flag minoxidil for review. The cleanest solution is a one-page Letter of Medical Necessity (LMN) from a physician or nurse practitioner that:

1. States the diagnosis (androgenetic alopecia, ICD-10 L64.9)
2. Specifies minoxidil 5% topical as the recommended treatment
3. Notes the expected duration of use (typically "ongoing maintenance")

Most administrators accept an LMN without further challenge. HealthRX providers can generate this letter as part of a standard telehealth visit.

Calculating the Pre-Tax Savings

A patient in the 22% federal income tax bracket purchasing $120 worth of minoxidil per year saves approximately $26.40 in federal taxes by paying through an HSA or FSA rather than with after-tax dollars. That savings compounds with any applicable state income tax deduction.

How Telehealth Prescriptions Affect Coverage Access

Although minoxidil 5% is available OTC, obtaining a formal prescription from a telehealth provider can open doors that OTC cash-pay cannot.

Prescription vs. OTC at the Pharmacy Counter

When a prescription is submitted to a pharmacy, the claim routes through the pharmacy benefit manager (PBM) rather than the OTC cash register. For patients with:

• Medicaid in a covered state: the prescription triggers PDL adjudication, potentially resulting in a $0, $3 copay.
• Commercial insurance with a drug benefit: many plans cover generic minoxidil at a low-tier copay when prescribed, even though it is available OTC.
• Medicare Part D: Part D plans are permitted but not required to cover OTC drugs. A small number of Part D plans do include minoxidil if prescribed, particularly Enhanced Alternative plans that include OTC benefits.

A 2022 CMS report on Part D formulary design noted that 14% of standalone Part D plans included at least one OTC drug when dispensed on a prescription.

Telehealth Prescription Workflow

For patients in states where Medicaid covers minoxidil with a PA, the telehealth visit generates the diagnosis code, clinical documentation, and PA request simultaneously, cutting the administrative burden to a single appointment. HealthRX providers follow a standardized intake that collects scalp photography, family history, and prior treatment data, which supports PA approval at first submission in most payer reviews.

Comparing Total Annual Cost Across Access Pathways

| Access Pathway | Estimated Annual Cost | PA Required | Rx Needed | |---|---|---|---| | OTC cash (generic, Walmart) | $96, $120 | No | No | | GoodRx at chain pharmacy | $101, $167 | No | No | | Cost Plus Drugs mail order | $108 | No | No | | Warehouse club 6-month pack | $56, $70 | No | No | | HSA/FSA OTC (22% bracket) | $73, $92 (after tax savings) | No | LMN recommended | | Medicaid Tier 1 (covered state) | $0, $36 ($0, $3 copay x 12) | No | Yes | | Medicaid Tier 2 (covered state) | $0, $36 (if PA approved) | Yes | Yes | | Commercial insurance, Tier 1 Rx | $0, $60 | Varies | Yes |

Who Qualifies for Medicaid-Covered Minoxidil

Even in states that cover minoxidil, not every Medicaid beneficiary automatically receives it. Standard qualification criteria typically include:

Eligibility Requirements Across Covered States

• Active Medicaid enrollment under any eligibility category (MAGI, disabled adult, aged, or pregnant)
• Documented diagnosis of androgenetic alopecia or alopecia (ICD-10 L64.0 through L64.9) by a licensed provider
• Age range: most PDLs cover adults 18 and older; pediatric use is generally not reimbursed because androgenetic alopecia is rare in children and minoxidil is not FDA-approved for patients under 18

Alopecia areata (L63.x), a separate autoimmune condition, is sometimes covered under different criteria and through different drug classes. Minoxidil may be used off-label adjunctively, but coverage determinations for L63.x claims vary by state and by individual managed care plan.

Prior Authorization Criteria in Tier 2 States

For states requiring PA, the clinical criteria generally mirror those used in commercial insurance: documentation of androgenetic alopecia for at least six months, two or more clinic visits or photographs confirming progression, and absence of a contraindication (hypotension, scalp dermatitis, or allergy to minoxidil or propylene glycol). The American Academy of Dermatology's 2023 guidelines on androgenetic alopecia list minoxidil as a Level I, Grade A recommended treatment.

Safety Profile and Prescribing Considerations

Access decisions should account for the drug's safety record, which is strong for a topically applied agent.

Adverse Effect Rates From Clinical Data

In the key 48-week multicenter trials, the most common adverse events with minoxidil 5% solution were:

• Hypertrichosis (unwanted facial or body hair growth): 3 to 7% of women; less common in men
• Contact dermatitis: approximately 7% overall, often attributable to the propylene glycol vehicle rather than minoxidil itself
• Scalp irritation or dryness: approximately 5%
• Systemic absorption and cardiovascular effects: rare at topical doses; case reports exist but the risk at the 5% concentration applied to an intact scalp is very low per FDA labeling

The FDA label for Rogaine Extra Strength documents maximum serum concentrations after topical application of approximately 1 to 2 ng/mL, far below the antihypertensive threshold.

The foam formulation contains no propylene glycol, making it the preferred option for patients with a history of contact allergy to the solution vehicle.

Pregnancy and Lactation

Minoxidil is classified as FDA Pregnancy Category C. Animal studies showed fetal harm at doses far exceeding human topical exposure, but adequate human data are lacking. The drug should be avoided during pregnancy. Lactation risk data are insufficient per LactMed (NIH), which rates minoxidil topical as "probably compatible" with breastfeeding based on low estimated infant dose but recommends caution.

Practical Steps for Patients and Prescribers in 2026

Getting coverage or the lowest possible cash price involves a specific sequence of actions, not a general search.

Step-by-Step Access Protocol

1. Confirm state Medicaid PDL status. Go to your state Medicaid agency website and search the current preferred drug list for "minoxidil" or NDC codes 00168-0208-xx (Perrigo) or 45802-0046-xx (Amneal). PDLs are typically posted as searchable PDFs updated quarterly.

2. Request a telehealth prescription if you are in a covered state. A prescription routes the claim through the pharmacy benefit and triggers the $0, $3 copay. Without the prescription, the claim routes as an OTC cash purchase.

3. Submit a PA request on the same day as the visit if required. PA turnaround in most states is 72 hours by law for non-urgent requests and 24 hours for urgent requests per 42 CFR § 431.244.

4. Use GoodRx or Cost Plus Drugs as the fallback. If PA is denied or the state does not cover the drug, a GoodRx coupon at Walmart brings the monthly cost to approximately $8, $9. Print the coupon before arriving at the pharmacy counter; the coupon price is not automatically applied.

5. Pay with an HSA or FSA card. Even without insurance coverage, pre-tax purchasing reduces net cost by 22 to 37% depending on the patient's marginal tax rate.

6. Buy a 90-day supply whenever possible. The per-unit cost drops by 20 to 30% with larger supply purchases, and adherence is higher with less frequent purchase trips.

The CDC's Healthy People 2030 framework identifies medication affordability as a social determinant of health, directly linked to treatment adherence rates across chronic conditions.

Frequently Asked Questions